A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma Who Are at Risk for Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant (ASCT)

Trial Profile

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma Who Are at Risk for Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant (ASCT)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Registrational
  • Acronyms PATH
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 10 Dec 2013 Final results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 15 Jul 2013 This trial is recruiting in Belgium, France, United Kingdom and discontinued in Spain, Italy as reported by European Clinical Trials Database record.
    • 31 May 2012 Planned End Date changed from 1 Mar 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top